JPMorgan raised the firm’s price target on Neurocrine (NBIX) to $184 from $183 and keeps an Overweight rating on the shares after surveying 24 ...

Over the last 7 days, the United States market has risen by 1.8%, contributing to a 10% increase over the past year, with earnings projected to grow by 14% annually in the coming years. In this ...

Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds ...

Ingrezza (valbenazine) comes hot on the heels of a rival drug from Teva, Austedo (deutetrabenazine) which gained FDA clearance for the treatment of chorea associated with Huntington’s disease ...

Envestnet Portfolio Solutions Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) ...

Corient Private Wealth LLC grew its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 64.0% during the ...

The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal ...

The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital ...

Meanwhile, the pharmacological pipeline for Tourette's is thin, with disappointing results for Teva's deutetrabenazine and Neurocrine Bio's Ingrezza (valbenazine) in phase 3 trials. At the moment ...

This type of medication can help manage the uncontrolled movements that can occur with Huntington’s disease. Huntington’s disease is a neurodegenerative disorder that causes a progressive ...

CHICAGO — In the RIVAWAR trial, patients hospitalized for a heart attack who were treated with rivaroxaban for left ventricular thrombus had comparable outcomes at 3 months to patients treated ...